Advertisement
Screener

INTELLIA THERAPEUTICS, INC. (NTLA) Stock Issued During Period, Value, Employee Stock Purchase Plan

2.8 / 5 stars · 68/120 Roast Me

INTELLIA THERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • INTELLIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $1.52M, a 22.88% increase year-over-year.
  • INTELLIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $1.24M, a 25.88% decline year-over-year.
  • INTELLIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $1.67M, a 18.63% decline year-over-year.
  • INTELLIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $2.05M, a 92.04% increase year-over-year.
  • INTELLIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $2.59M, a 13.30% decline from fiscal 2024.
  • INTELLIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $2.99M, a 24.00% decline from fiscal 2023.
  • INTELLIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $3.93M, a 48.32% increase from fiscal 2022.
  • INTELLIA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $2.65M, a 30.88% increase from fiscal 2021.
Period endStock Issued During Period, Value, Employee Stock Purchase Plan 3 monthStock Issued During Period, Value, Employee Stock Purchase Plan 12 month
2026-06-30$1.52M
10-Q · filed 2026-08-06
2025-12-31$2.59M
10-K · filed 2026-02-26
2025-06-30$1.24M
10-Q · filed 2026-08-06
2024-12-31$2.99M
10-K · filed 2026-02-26
2024-06-30$1.67M
10-Q · filed 2025-11-06
2023-12-31$3.93M
10-K · filed 2026-02-26
2023-06-30$2.05M
10-Q · filed 2024-11-07
2022-12-31$2.65M
10-K · filed 2025-02-27
2022-06-30$1.07M
10-Q · filed 2023-11-09
2021-12-31$2.02M
10-K · filed 2024-02-22
2021-06-30$970.00K
10-Q · filed 2022-11-03
2020-12-31$1.56M
10-K · filed 2023-02-23
2020-06-30$685.00K
10-Q · filed 2021-11-04
2019-12-31$1.09M
10-K · filed 2022-02-24
2019-06-30$534.00K
10-Q · filed 2020-11-05
2018-12-31$1.02M
10-K · filed 2021-02-26
2018-06-30$598.00K
10-Q · filed 2019-10-31
2017-12-31$825.00K
10-K · filed 2020-02-27
2016-12-31$259.00K
10-K · filed 2019-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Celldex Therapeutics, Inc. (CLDX)United States$2.471B-9.72
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
NEOGEN CORP (NEOG)United States$2.979B-247.49
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93